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Abstract
Testing for associations in big data faces the problem of multiple comparisons, with true signals 
difficult to detect on the background of all associations queried. This is particularly true in human 
genetic association studies where phenotypic variation is often driven by numerous variants of 
small effect. The current strategy to improve power to identify these weak associations consists of 
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applying standard marginal statistical approaches and increasing study sample sizes. While 
successful, this approach does not leverage the environmental and genetic factors shared between 
the multiple phenotypes collected in contemporary cohorts. Here we develop Covariates for Multi-
phenotype Studies, an approach that improves power when correlated variables have been 
measured on the same samples. Our analyses over real and simulated data provide direct support 
that correlated phenotypes can be leveraged to achieve dramatic increases in power, often 
surpassing the power equivalent of a two-fold increase in sample size.
Introduction
Performing agnostic searches for association between pairs of variables in large-scale data, 
using either common statistical techniques or machine learning algorithms, faces the 
problem of multiple comparisons. This is particularly true for genetic association studies, 
where contemporary cohorts have access to millions of genetic variants as well as a broad 
range of clinical factors and biomarkers for each individual. With billions of candidate 
associations, the identification of a true association of small magnitude is extremely 
challenging. Standard analysis approaches currently consists of looking at the data in one 
dimension (i.e. testing a single outcome with each of the millions of candidate genetic 
predictors) and applying univariate statistical tests – the commonly named GWAS (genome-
wide association study) approach1, 2. To increase power, GWAS rely on increasing sample 
size in order to reach the multiple comparisons adjusted significance level. The largest 
studies to date, including hundreds of thousands of individuals across dozens of cohorts, 
have pushed the limit of detectable effect sizes. For example, researchers are now reporting 
genetic variants explaining less than 0.01% of the total variation of body mass index (BMI)3.
In addition to the substantial financial costs of collecting and genotyping large cohorts, this 
brute force approach has practical limits. More importantly, this approach does not leverage 
the large amount of additional phenotypic and genomic information measured in many 
studies. Joint analyses of multiple phenotypes with each predictor of interest (e.g. Manova, 
MultiPhen)4–6 offer a gain in power, but have three major drawbacks. First, a significant 
result can only be interpreted as an association with any one of the phenotypes. While this is 
useful information for screening purposes, it is insufficient to identify specific genotype-
phenotype associations6. Second, it makes the replication process difficult, since all 
genotype-phenotype pairs must be considered. Third, joint tests have lower power than 
univariate tests when only a small proportion of the phenotypes are associated with the 
tested genetic variant. This is a simple problem of dilution; a small number of true 
associations mixed with many null phenotypes will reduce power.
In this work, we develop CMS (covariates for multi-phenotype studies), a method that 
improves association test power in multi-phenotype studies, while providing the resolution 
of univariate tests. When testing for association between a genotype and a phenotype CMS 
allows the other collected correlated phenotypes to serve as covariates. The core of the 
method is a principled approach to selecting a set of these covariates that are correlated with 
the phenotype, but not with the genotype, thereby reducing phenotypic variance independent 
of the genotype and concomitantly increasing power. We show via application to simulated 
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and real data sets that CMS scales to thousands of phenotypes, produces gains in power 
equivalent to a two- to three-fold increase in sample size, and outperforms other recently 
proposed multi-phenotype approaches with univariate resolution including a Bayesian 
approach (mvBIMBAM7), and dimensionality reduction approaches (PCA8, PEER9).
Results
Covariates as proxy for unmeasured causal factors
The objective of this work is to develop a method that keeps the resolution of univariate 
analysis when testing for association between an outcome Y and candidate predictor X, but 
takes advantage of other available covariates  to increase power. 
Consider the inclusion of covariates correlated with the outcome in a standard regression 
framework. This may increase the signal-to-noise ratio between the outcome and the 
candidate predictor when testing: , where . The selection of which 
covariates  are relevant to a specific association test is usually based on causal 
assumptions10, 11. Epidemiologists and statisticians commonly recommend the inclusion of 
two types of covariates when testing for association between X and Y: those that are 
potential causal factors of the outcome and independent of X, and those that may confound 
the association signal between X and Y, i.e. variables such as principal components (PCs) of 
genotypes or covariates that capture undesired structure in the data that can lead to false 
associations12. All other variables that vary with the outcome because of shared risk factors 
are usually ignored. However, those variables carry information about the outcome, and 
more precisely about the risk factors of the outcome. Because they potentially share 
dependencies with the outcome, they can be used as proxies for unmeasured risk factors. As 
such, they can be incorporated in  to improve the detection of associations between X and 
Y. However, when these variables depend on the predictor X, using them as covariates can 
lead to both false positive and false negative results depending on the underlying causal 
structure of the data.
The presence of interdependent explanatory variables, also known as multicollinearity13, can 
induce bias in the estimation of the predictor’s effect on the outcome. We recently discussed 
this issue in the context of genome-wide association studies that adjusted for heritable 
covariates14. To illustrate this collider bias, consider first the simple case of two independent 
covariates  and  that are true risk factors of Y. When testing for association between X 
and Y, adjusting for  and  can increase power, because the residual variance of Y after 
the adjustment is smaller while the effect of X is unchanged (Fig. 1a), i.e. the ratio of the 
outcome variance explained by X over the residual variance is larger after removing the 
effect of  and . However, in practice, true risk factors of the outcome are rarely known. 
Consider instead the more realistic scenario where  and  are unknown but a covariate C, 
which also depends on those risk factors, has been measured. Because of their shared 
etiology, Y and C display positive correlation, and when X is not associated with C, 
adjusting Y for C increases power to detect ( ) associations (Fig. 1b). Problems arise 
when C is associated with X. In this case adjusting Y for C biases the estimation of the 
effect of X on Y, decreasing power when the effect of X is concordant between C and Y 
(Fig. 1c), and inducing false signal when the effect is discordant (in opposite direction or 
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when X is not associated with Y, Fig. 1d). The same principles apply when including 
multiple covariates correlated with the outcome.
When none of the covariates depend on the predictor (Fig. 1a-b), their inclusion in a 
regression can reduce the variance of the outcome without confounding, leading to increased 
statistical power while maintaining the correct null distribution. This gain in power can be 
easily translated in terms of a sample size increase. The noncentrality parameter (ncp) of the 
standard univariate chi-square test between X and Y is  where 
N,  and are the sample size, the total variance of the outcome Y, and the squared 
correlation between X and Yrespectively. When reducing  by a factor  through covariate 
adjustment, and assuming the effect of X on Y is small, so that ,  can be 
approximated by . For example, when the covariates 
explain 30% of the variance of Y, the power of the adjusted test is equivalent to analyzing 
approximately a 1.4 fold larger sample size (as compared to the unadjusted test). When 
covariates explain 80% of the phenotypic variance –a realistic proportion in some genetic 
datasets examined below– the power gain is equivalent to a five-fold increase in sample size 
(Fig. 2a).
Selecting covariates for each outcome-predictor pair
The central problem that must be solved is how to select a subset of the available covariates 
to optimize power while preventing induction of false positive associations between the 
outcome and the predictor. To do this, all covariates associated with the outcome should be 
included except those also associated with the predictor. A naïve solution would consist of 
filtering out covariates based on a p-value threshold from the association test between each 
covariate and the predictor (e.g. removing predictors with a predictor-covariate association 
p-value < 0.05). However, unless the sample size is infinitely large, type I covariates (i.e. 
covariates associated with the predictor) will be included. Furthermore, such a filtering also 
implies that some type II covariates (i.e. covariates not associated with the predictor) will be 
removed because they incidentally pass the p-value threshold. Interestingly, removing type II 
covariates using this approach not only results in a sub-optimal test, it also induces an 
inflated false positive rate (Supplementary Fig. 1). In brief, when the outcome and the 
covariate are correlated, low predictor-covariate p-value implies low predictor-outcome p-
value. As a result, the p-value distribution from the subset of predictor-outcome unadjusted 
statistics (i.e. those for which the predictor-covariate p-value is below the threshold) is 
enriched for low p-value, resulting in an overall type I error inflation for the approach 
(Supplementary Note and Supplementary Fig. 2).
In this work, we develop a computationally efficient heuristic to improve the selection of 
type II covariates while removing type I covariates that we refer further to as CMS 
(Covariates for Multi-Phenotype Studies). We present an overview of the approach, with 
complete details of the algorithm provided in the online Methods and the Supplementary 
Note.
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Let  and  be the marginal estimated regression coefficients between  and C, and between 
X and  (not adjusted for C) respectively, and let  be the estimated correlation between Y 
and C. Naive p-value based filtering, i.e. unconditional filtering on , assumes that under the 
null ( )  is normally distributed with  and variance , where n is the sample 
size. The central advance of CMS is to additionally use the expected mean and variance of 
conditional on  under a complete null model ( ). We show that this can be 
approximated as:  and  (Supplementary 
Note, and Supplementary Fig. 3).
The bias observed from naïve univariate p-value filtering (Supplementary Fig. 1) is induced 
by the misspecification of the expected mean and variance of the predictor-covariate effect 
estimate when the predictor is associated with neither the outcome, nor the covariates. 
Figure 3a illustrates  inclusion area for a p-value threshold of 5% –i.e. if  is outside the 
inclusion area, the covariate  is filtered out –based on the unconditional distribution. As 
shown in Supplementary Table 1 and Supplementary Figure 4, which describes the simple 
case of a single covariate, using the distribution of  conditional on  to select covariates is 
also poor solution, resulting in a deflated test statistic for  due to an overestimation of the 
standard error of  when adjusting for the selected covariates. The improvement from CMS 
is derived from defining the inclusion area as a combination of the unconditional and 
conditional distributions of  (Figure 3b,c). This solves the inflation observed in 
Supplementary Fig. 1 and leads to a valid test under the complete null model with a variable 
number of available covariates (see Supplementary Fig. 3 and Supplementary Table 1).
Finally, to reduce the risk of false positives, the algorithm scales inclusion areas on the basis 
of total amount of the outcome’s variance explained by  and . To further improve the 
performance of filtering covariates we also consider omnibus association test between 
and Y, which is more effective when multiple covariates have small to moderate effects (see 
Supplementary Note).
Simulated data analysis and method comparisons
We first assessed the performance of the proposed method through a simulation study in 
which we generated series of multi-phenotype datasets over an extensive range of parameter 
settings (see online Methods and Supplementary Note). Each dataset included n individuals 
genotyped at a single nucleotide polymorphism (SNP) with minor allele frequency (MAF) 
drawn uniformly from [0.05, 0.5], a normally distributed phenotype Y, and 
correlated covariates . Under the null, the SNP does not contribute to the 
phenotype and under the alternate the SNP contributes to the phenotype under an additive 
model. In some datasets, the SNP also contributes to a fraction  of the 
covariates. These are the covariates, which we wish to identify and filter out of the 
regression. We considered sample sizes n of 300, 2,000 and 6,000, we varied , the variance 
of Y explained by C, from 25% to 75%. We varied the effect of the predictor on Y and C, 
when relevant, from almost undetectable (i.e. median ) to relatively large (i.e. median 
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). For each choice of parameters, we generated 10,000 replicates and performed four 
association tests: (unadjusted) linear regression (LR), linear regression with covariates 
included based on p-value filtering at an  threshold of 0.1 (FT), CMS, and an oracle 
method that includes only the covariates not associated with the SNP (OPT), this being the 
optimal test regarding our goal. We considered a total of 432 scenarios and as shown in 
Figure 4 and Supplementary Tables 2-4 the type I error rate of CMS is well calibrated across 
parameter ranges. Note that we did not consider strategies which include all 
variables as covariates, MANOVA, or “reverse regression” (i.e. MultiPhen)5, as these 
approaches lead to substantial inflation of type I error rate (see Supplementary Fig. 5).
We compared the performances of CMS against other recently proposed multi-phenotype 
approaches including mvBIMBAM. The CMS approach was more than 100 fold faster than 
mvBIMBAM and the two methods showed similar accuracy when compared using ROC 
curves (Supplementary Fig. 6). We also considered data reduction techniques aimed at 
modelling hidden structure. For each dataset we tested the association between the primary 
outcome and the genotype while adding principal components (PCs) or PEER factors. We 
observed increasing type I error rates when increasing the number of PCs or PEER factors in 
the model (Supplementary Figure 7). Furthermore, at a fixed false positive rate, when we 
applied CMS on top PEER factors, we found that CMS substantially increases power above 
those gains available from PEER (Supplementary Fig. 8 and Supplementary Note).
Real data analysis
We first analyzed a set of 79 metabolites measured in 1192 individuals genotyped at 668 
candidate SNPs. We derived the correlation structure between these metabolites (Fig. 2b and 
Supplementary Fig. 9)3 and estimated the maximum gain in power that can be achieved by 
our approach in these data. The proportion of variance of each metabolite explained by the 
other metabolites varied between 1% and 91% (Fig. 2b). This proportion is higher than 50% 
for two thirds of the metabolites, equivalent to a two-fold increase in sample size. For 10% 
of the metabolites, other variables explain over 80% of the variance, corresponding to a five-
fold increase in sample size. In such cases, predictors explaining less than 1% of 
metabolite’s variation can change from undetectable (power<1%) to fully detectable 
(power>80%).
We performed a systematic screening for association between each SNP and each 
metabolite, using both a standard univariate linear regression adjusting for potential 
confounding factors and using CMS to identify additional covariates. Overall, both tests 
showed correct  (Supplementary Fig. 10a). We focused on associations significant after 
Bonferroni correction (P < 9.5×10−7 corresponding to the 52,772 tests performed). The 
standard unadjusted approach (LR) detected 5 significant associations. In comparison, the 
CMS approach identifies 10 associated SNPs (Table 1), including four of the five 
associations identified by LR. In most cases the p-value of CMS was dramatically lower 
(e.g. 1000 fold smaller for rs780094 – alanine). Comparing these results to four independent 
GWAS metabolite scans of larger sample size (N equal 8,330, 7,824, 2,820, and 2,076 for 
Finnish15, KORA+TwinsUK,16, 17 and FHS,18 respectively), we found that all metabolite/
gene associations only identified by CMS replicated (Supplementary Table 5).
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This analysis confirms the power of CMS, highlighting its ability to identify variants with 
much smaller sample size. Interestingly, the only association identified by the unadjusted 
analysis (lactose and GC, P=6.1×10−7) and not confirmed by CMS (P=6.3×10−6) was also 
the only one that did not replicate in the larger studies. Note that in the analysis presented in 
Table 1, we followed the identical analysis approach of the previous studies and did not 
adjust for either PCs or PEER factors9. However, adjusting did not qualitatively change the 
results. For example, we considered adjusting for 5, 10, and 20 PCs and obtained 11, 15 and 
17 hits for CMS and 9, 11, and 5 hits for LR with PC covariates (Supplementary Table 6). 
The overall replication rate was lower when including PCs, consistent with the higher false 
positive rate we observed in our simulations.
We then considered genome-wide cis-eQTL mapping in RNA-seq data from the gEUVADIS 
study. Gene expression is a particularly compelling benchmark, as the gold standard 
analyses already use an adjustment strategy to account for hidden factors in eQTL 
GWAS9, 19. Here we used the PEER approach9 to derive hidden factors, as this method was 
applied in the original analysis20. After stringent quality control the data included 375 
individuals of European ancestry with expression estimated on 13,484 genes, of which 
11,675 had at least one SNP with a MAF ≥ 5% within 50kb of the start and end sites.
We observed that expressions levels between genes were highly correlated (Fig. 2c), an ideal 
scenario for CMS. We first performed a standard cis-eQTL screening using linear regression 
(LR), testing each SNP within 100kb of each available gene for association with overall 
normalized RNA level while adjusting for 10 PEER factors, for a total of ~1.3 million tests. 
Then, we applied CMS to identify, for each test, which other gene’s RNA levels could be 
used as covariates on top of the PEER factors. As shown in Supplementary Figure 10b, both 
LR and CMS showed large number of highly significant associations. For comparison 
purposes we plotted the most significant SNP per gene obtained with the standard approach 
against those obtained with CMS in Figure 5. As shown in this figure, 2,725 genes had a 
least one SNP significant with both methods, and 56 genes were identified by the standard 
approach only. Conversely 657 genes were found only with CMS, corresponding to a 24% 
increase in detection of cis-eQTL loci. This indicates that by being gene/SNP specific, CMS 
is a priori able to recover substantial additional variance, allowing for increased power 
(Table 2 and Supplementary Table 7).
To assess the validity of our results we performed an in-silico replication analysis using two 
databases of known eQTLs21, 22. We found that 35% of the SNP-gene associations found by 
both LR and CMS replicated. For the subset of association found only by CMS the 
replication rate was 20%, similar to the results from the LR only replication, which was 
22%. The replication rate was 6% for genes without a CMS or LR association. The 
replications were primarily in LCL (Table 2), and the replication rate for our study is within 
the same range as the replication rate from previous LCL studies (Supplementary Table 8), 
confirming that a substantial number of the additional associations identified by CMS 
correspond to real signal (see Supplementary Note). Additional GC correction of the p-
values using inflation factors form a null experiment ( =1.01, and =1.05, 
Supplementary Fig. 11) did not qualitatively change the results.
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Discussion
Growing collections of high-dimensional data across myriad fields, driven in part by the “big 
data revolution” and the Precision Medicine Initiative, offer the potential to gain new 
insights and solve open problems. However, when mining for associations between collected 
variables, identifying signals within the noise remains challenging. While univariate analysis 
offers precision, it fails to leverage the correlation structure between variables. Conversely, 
joint analyses of multiple phenotypes have increased power at the cost of decreased 
precision. We demonstrated in both simulated and real data that the proposed method, CMS, 
maintains the precision of univariate analysis, but can still exploit global data structures to 
increase power. Indeed, in the data sets examined in this study we observed up to a 3-fold 
increase in effective sample size in both the gene expression and metabolites data thanks to 
the inclusion of relevant covariates (Supplementary Figure 12).
CMS can be applied generally, but is particularly well suited to the analysis of genetic data 
for several reasons. First, the genetic architectures of many complex phenotypes are 
consistent with a polygenic model with many genetic variants of small effect size that are 
difficult to detect using standard approaches23. Second, many correlated phenotypes share 
genetic and environmental variance without complete genetic overlap24. Third, the 
underlying structure of the genomic data is relatively well understood with an extensive 
literature on the causal pathway from genotypes to phenotypes through direct and indirect 
effects on RNA, protein and metabolites (Supplementary Fig. 13 and Supplementary Note). 
Finally, when the predictors of interests are genetic variants, there is less concern regarding 
potential confounding factors. The only well-established confounder of genetic data is 
population structure and this can be easily addressed using standard approaches12. For other 
types of data, when the underlying structure of the data is unknown the risk for introducing 
bias is high.
Several other groups have considered the problem of association testing in high-dimensional 
data while maintain precision. In genetics, multivariate linear mixed models (mvLMMs) 
have demonstrated both precision and increases in power when correlated phenotypes are 
tested jointly. However, mvLMMs are only exploiting the genetic similarity of phenotypes 
and are not computationally efficient enough to handle dozens of phenotypes jointly4. CMS 
leverages both genetic and environmental correlations and can be easily adapted to hundreds 
or thousands of phenotypes as we demonstrated here. Instead, we compared CMS to other 
more related approaches, including the Bayesian approach mvBIMBAM, and adjustment for 
hidden factors inferred from either principal component analysis or PEER. We found that 
mvBIMBAM and CMS had very similar accuracy as measured by the AUC, while 
mvBIMBAM was approximately 100 fold slower, and applicable only to a small number of 
phenotypes (i.e. <10). As for strategies that reconstruct hidden variables, we found that they 
can induce false positives25, and are suboptimal compared to CMS. Indeed, the gEUVADIS 
analysis showed a 24% increase in the detection of eQTL when applied on top of PEER 
factor adjustment.
There are several caveats to our approach. First, the proposed heuristic is conservative by 
design to avoid false association signals and so all the available power gain is not achieved. 
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Second, while all simulations we performed show strong robustness, it remains a heuristic as 
are other methods9, 19. Ultimately, we recommend external replication to validate results and 
effect size, as is standard in genetic studies. Third, CMS is more computationally intensive 
than methods such as PCA or PEER. Fourth, CMS assumes that the variables are measured 
and available on all samples. The current implementation includes a naïve missing data 
imputation and simple case-scenario simulations showed this strategy has minimum impact 
on the robustness of CMS (supplementary Fig. 14). However more advanced approaches 
have been developed26. Fifth, while the principles we leveraged are likely applicable to 
categorical and binary outcomes (see27 for logistic regression), our algorithm is currently 
only applicable to continuous outcomes. Sixth, for monogenic disorders, or phenotypes 
without intermediately measured endophenotypes, CMS is unlikely to result in power gains.
We focused on association screening and aimed at optimizing power and robustness. 
However, the selection of covariates performed by CMS might carry information about 
which covariates are operating through specific SNPs. Future work will explore whether 
output from CMS can generate hypotheses on the underlying causal model. There are other 
additional improvements not specific to CMS worth exploring. In particular, when multiple 
phenotypes are considered as outcomes then a multiple test correction penalty must be 
selected to account for all tests across all phenotypes. In this study, we applied a Bonferroni 
correction, not accounting for the correlation between outcomes. This is a conservative 
correction and more powerful approaches are possible28.
Large-scale genomic data have the potential to answer important biological questions and 
improve public health. However, those data come with methodological challenges. Many 
questions, such as improving risk prediction or inferring causal relationships rely on our 
ability to identify associations between variables. In this study, we provide a comprehensive 
overview of how leveraging shared variance between variables can be used to fulfill this 
goal. Building on this principle we developed the CMS algorithm, an innovative approach 
which can dramatically increase statistical power to detect weak associations.
Online Methods
The CMS algorithm
We develop an algorithm to select relevant covariates when testing for association between a 
predictor X and an outcome Y. For a set of candidate covariates , the 
filtering is applied on  and , the estimated marginal effect of the predictor X on  and its 
associated p-value, respectively. It uses four major features: i)  the total amount of 
variance of Y explained by the C ; ii) )the estimated effect of each  on Y and 
their joint effect respectively; iii) , the estimated effect of X on Y from the marginal model 
; and iv) , the p-value for the multivariate test of all  and X, which is 
estimated using a standard multivariate approach (i.e. MANOVA).
Filtering is applied in two steps using the aforementioned features and additional parameters 
described thereafter. Step 1 is an iterative procedure focusing on . It consists in 
removing potential covariates until  reaches , a p-value threshold set to 0.05 by 
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default. This step is effective at removing combination of covariates with strong to moderate 
effects, but will potentially leave weakly associated covariates.
Step 2 is also iterative and uses covariates pre-selected at step 1. It consists in deriving two 
confidence intervals  and , for the expected distribution of  conditional on 
under a complete null model (  and ), and the unconditional distribution of , 
respectively. The unconditional distribution of  can be approximated as , 
while the conditional distribution is , where  is the estimated 
correlation between Y and C (see Supplementary Note). The inclusion area for each  is 
defined as the union of  and , which are determined from the conditional and 
unconditional distributions, ), , and distribution-specific weights  and  we 
further introduced to improve power and robustness. Specifically, 
and 
 where ,  and 
 are the unconditional and conditional means and standard deviations 
respectively.
The weights  and  are always less than 2 and shrink the size of the inclusion area. To 
get (  we first set a stringency parameter 
, which decreases as 
increase. This makes the inclusion area smaller as the covariate  being considered explains 
more of the variance of Y. The purpose of this parameter is to decrease the risk of false 
positives because bias will be enhanced when the residual variance of the outcome is 
reduced14. This is illustrated in Figure 3, where the unconditioned inclusion area from CMS 
is smaller than for the standard approach.
As  increases, the likelihood of the true  being null decreases and we want , and the 
conditional interval , to shrink to zero. We use a simple linear function for with a 
transition that corresponds to the point where the 95% CI of the observed  and  stop 
overlapping. The former CI approximately equal , where  is the 
standard deviation of X, while the later equals . Expressed as chi-squared 
this transition point corresponds to . We set 
and  where  and are defined below to linearly scale 
with respect to this transition point.
Altering the transition point or scaling the inclusion interval can increase the risk of false 
positives or decrease power (Supplementary Figs. 15–17). We chose the CMS parameters 
conservatively to prevent false positives, however, alternative approaches such as cross 
validation may identify parameters that increase the power of CMS while maintaining a 
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calibrated null distribution. Interestingly, the omnibus association test between  and Y 
has very little impact on the overall performance (Supplementary Fig. 17) with the 
parameters used here.
Finally, because of multicollinearity, the estimated  can vary substantially depending on 
which other covariates  is already included in the model. As a result,  cannot be 
estimated from a marginal model such as . To address, this issue we implemented 
the selection of covariates into an iterative loop where  terms are re-estimated 
each time a candidate covariate is excluded.
The complete CMS algorithm is provided in the Supplementary Note.
Simulations
We simulated series of genetic and phenotypic datasets under a variety of genetic models to 
interrogate the properties of the proposed test. Each dataset included n individuals 
genotyped at a single nucleotide polymorphism (SNP), a normally distributed phenotype Y, 
and  correlated covariates . Genotypes g for each of 
individuals were generated by summing two samples from a binomial distribution with 
probability uniformly drawn in [0.05, 0.5] and then normalized to have mean 0 and variance 
1. Under the null, the SNP does not contribute to the phenotype and under the alternate the 
SNP contributes to the phenotype under an additive model. In some datasets, the SNP also 
contributes to a fraction  of the covariates. These are the covariates, 
which we wish to identify and filter out of the regression. The remaining variance for each 
phenotype, which represents the remaining genetic and environmental variance, was drawn 
from a m+1-dimensional multivariate normal distribution with mean 0 and variance C. In 
instances where this matrix was not positive definite we used the Higham algorithm29 to find 
the closest positive definite matrix. The diagonal of the covariance matrix was specified as 1 
minus the effect of g (if relevant) such that the total variance of each phenotype had an 
expected value of 1.
We considered sample sizes n of 300, 2,000 and 6,000, we varied , the variance of Y 
explained by C, from 25% to 75%. We varied the effect of the predictor on Y and C, when 
relevant, from almost undetectable (i.e. median ) to relatively large (i.e. median 
). For each choice of parameters, we generated 10,000 replicates and performed four 
association tests: (unadjusted) linear regression (LR), linear regression with covariates 
included based on p-value filtering at an  threshold of 0.1 (FT), CMS, and an oracle 
method that includes only the covariates not associated with the SNP (OPT), this being the 
optimal test regarding our goal. For each null model we derived the genomic inflation 
factor30 , while for the alternative model we estimated power at an  threshold of 
5×10−7, to account for the 100,000 tests performed. All tests were two-sided. Results for 
each of the 432 scenarios considered are presented in Supplementary Figs. 18–44.
To comprehensively summarize the performance of the different tests across these scenarios, 
we randomly sampled subsets of the simulations to mimic real datasets while focusing on a 
sample size of 2,000 individuals and a total of 100,000 SNPs tested. For null models, we 
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assumed that two thirds (66%) of the genotypes are under the complete null (not associated 
with any covariate, ), while 27% are associated with a small proportion of the covariates 
( ), and the remaining 7% are highly pleiotropic ( ).
We compared the performances of CMS against other recently proposed multi-phenotype 
approaches. This includes mvBIMBAM, a Bayesian approach that aims to classify the 
outcome as directly associated, indirectly associated, or unassociated with the predictor. The 
mvBIMBAM approach has the main advantage of proposing a formal theoretical framework 
that, similar to structural equation modelling, explores a wide range of underlying causal 
models. However, there is a large computational cost, and the approach is currently limited 
to the analysis of a relatively small number of traits (<10). We therefore performed our 
comparison using small-scale simulated data (i.e. 10 phenotypes).
Other potential alternatives to CMS are data reduction techniques that aimed at modelling 
hidden structure. They have been widely-used for the analysis of molecular phenotypic data, 
with a primary goal of removing confounding effects8, 9, 19. We examined principal 
component analysis, as it has been widely used and is still one of the most popular 
approaches8, and a more complex factor analysis inspired method (PEER), which has 
outperformed similar methods9. We simulated series of large multivariate datasets under a 
null model, where a genotype is associated with multiple variables but not the primary 
outcome of interest (i.e. in the presence of type II covariates). For each dataset we tested the 
association between the primary outcome and the genotype while adding principal 
components (PCs) or PEER factors. Results from this experiment are presented in 
Supplementary Figure 7, and show an increasing type I error rates when increasing the 
number of PCs or PEER factors in the model.
Previous studies also observed that including fixed effects can improve power over 
dimensionality reductions approaches that incorporate these same variables31. This is likely 
driven by the shrink that is applied when these methods jointly fit effect sizes of multiple 
correlated variables. To investigate the power gains available to CMS when PCs/PEER 
factors are used we simulated data under an alternative model of true association but in the 
absence of type II covariates to avoid the aforementioned issue. We applied CMS on top of a 
variable number of PEER factors that were always included as covariates PEER 
(Supplementary Fig. 8).
The metabolite data
Circulating metabolites were profiled by liquid chromatography-tandem mass spectrometry 
(LC-MS) in prediagnostic plasma from 453 prospectively-identified pancreatic cancer cases 
and 898 controls. These subjects were drawn from four U.S. cohort studies: the Nurses 
Health Study (NHS), Health Professionals Follow-up Study (HPFS), Physicians Health 
Study (PHS) and Women’s Health Initiative (WHI). Two controls were matched to each case 
by year of birth, cohort, smoking status, fasting status at the time of blood collection, and 
month/year of blood collection. Metabolites were measured in the laboratory of Dr. Clary 
Clish at the Broad Institute using the methods described in Wang et al.32 and Townsend et al.
33
 A total of 133 known metabolites were measured; 50 were excluded from analysis 
because of poor reproducibility in samples with delayed processing (n=32), CV>25% 
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(n=13), or undetectable levels for >10% subjects (n=5). The remaining 83 metabolites 
showed good reproducibility in technical replicates or after delayed processing.33 Among 
those, 79 had no missing data and were considered further for analysis. Additional details of 
these data have can be found here34. Genotypic data was also available for some of these 
participants. A subset of 645 individuals from NHS, HPFS and PHS had genome-wide 
genotypes data as part of PanScan study35. Among the remaining participants, 547 have 
been genotyped for 668 SNPs chosen to tag genes in the inflammation, vitamin D, and 
immune pathways. To maximize sample size we focused our analysis on these 668 SNPS 
which were therefore available in a total of 1,192 individuals. In-sample minor allele 
frequency of these variants range from 1.1% to 50%. Metabolite levels were approximately 
Gaussian after adjusting for the confounding factors and were therefore not transformed 
further (Supplementary Figure 45). We first applied standard linear regression testing each 
SNP for association with each metabolite while adjusting for five potential confounding 
factors: pancreatic cancer case-control status, age at blood draw, fasting status, self-reported 
race, and gender. We then applied the CMS while also including the five confounding factors 
as covariates. All tests were two-sided.
The gEUVADIS data
The gEUVADIS data20 consists of RNA-seq data for 464 lymphoblastoid cell line (LCL) 
samples from five populations in the 1000 genomes project. Of these, 375 are of European 
ancestry (CEU, FIN, GBR, TSI) and 89 are of African ancestry (YRI). In these analyses, we 
considered only the European ancestry samples. Raw RNA-sequencing reads obtained from 
the European Nucleotide Archive were aligned to the transcriptome using UCSC annotations 
matching hg19 coordinates. RSEM (RNA-Seq by Expectation-Maximization)36 was used to 
estimate the abundances of each annotated isoform and total gene abundance is calculated as 
the sum of all isoform abundances normalized to one million total counts or transcripts per 
million (TPM). For each population, TPMs were log2 transform and median normalized to 
account for differences in sequencing depth in each sample. A total of 29,763 total genes 
were initially available. We removed those that appear to be duplicates or that had low 
expression value (defined as log2(TPM)<2 in all samples). After filtering, 13,484 genes 
remain. The genotype data was obtained from 1000 Genomes Project Phase 1 data set. We 
restricted the analysis to the SNPs with a MAF≥5% that were within ±50kB from the gene 
tested for cis-effect. A total of 11,175 genes had at least one SNP that match these criteria. 
We performed a standard cis-eQTL screening applying first standard linear regression while 
adjusting for PEER factors. We then applied CMS while including the same PEER factors as 
covariates. All tests were two-sided.
When running CMS, we performed a pre-filtering of the candidate covariates. More 
specifically, for each gene analyzed –referred further as the target gene– we restrained the 
number of candidate covariates (i.e. gene other than the target) to be evaluated. First, we 
aimed at avoiding genes which expression is more likely to be associated with some of the 
SNPs tested because of a cis-effect, as such genes are more likely to induce false signal. 
Thus, all genes in close physically proximity with the target genes (≤1Mb) were excluded. 
Second, we aimed at reducing the number of candidate covariates (13,484 minus 1, a priori), 
as most of them are likely uninformative and because our simulation showed that for small 
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sample size, CMS would have reduced robustness if the number of candidate covariates is 
too large. To do so we performed an initial screening for association between the target and 
all other genes and used the top 50 showing the strongest squared-correlation with the target.
We performed an in-silico replication analysis using two databases of known eQTLs. The 
first database included results from 15 publicly available studies (excluding the European 
gEUVADIS) from multiple tissues21, and a second one included eQTLs in whole blood 
samples from a joint analysis of 7 studies22. Summary statistics were not available for every 
SNP, instead these databases listed all SNPs found at an FDR of 5% in each study. 
Therefore, we could not perform a standard replication study and instead compared the 
replication rate of CMS and LR in these databases. Note that we expect smaller replication 
rate for the LR-only and CMS-only compared to those identified by both approaches, as the 
latter group includes variants with the largest effects, while the former ones correspond to 
associations of smaller magnitude. Finally, we performed a quasi-null experiment where we 
tested for trans-effects using random SNPs from the genome, assuming that the majority of 
these will be under the null.
Variance explained in multiple regressions
We plotted in Figure 2b-c the variance of a set of outcomes  that can be 
explained by covariates in the data –i.e. how much of the variance of  can be explained by 
. For illustration purposes, we also approximated the individual contribution of each 
covariate. In brief, we standardized all variables and estimated , the proportion of variance 
of the outcome explained by each  from the marginal models , and , the 
total variance of  explained by all  jointly, from the model . Then, we 
derived , an approximation of the relative contribution of each  to the variance of  as 
follows:
Note that this is an arbitrary re-scaling of the real contribution of the  variable. Indeed, 
the correlation between all  induces multicollinearity in the regression and it follows that 
.
Missing data
The current version of the algorithm includes a naïve imputation strategy for missing data 
that consists in replacing missing values of candidate covariates by their mean value. This 
allows avoiding the sharp decrease in sample size that could arise if the proportion of 
missing value is too large. Note that the inference is performed per predictor-outcome pair 
and only for the covariates while we do not infer missing values for the outcome or the 
predictor tested. We show in Supplementary Figure 14 that the imputation does not have a 
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strong impact on the robustness of the test, although we note that large-scale (i.e. ≥50% of 
missing values) random missingness appears to slightly deflate the test statistics from CMS.
Data availability
The gEUVADIS RNA-sequencing data, genotype data, variant annotations, splice scores, 
quantifications, and QTL results are freely and openly available with no restrictions at 
www.geuvadis.org. The Metabolites data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Code availability
An implementation of the approach is freely available at https://github.com/haschard/CMS
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Variance components of adjusted variables
We illustrate the components of the variance of an outcome Y before and after adjusting for 
other variables. The predictor of interest, X, is displayed in red. In (a), the adjusting 
variables (U1 and U2) are true causal factors that have direct effects on Y, therefore adjusting 
Y for U1 and U2 reduces the variance of Y. In (b) the true factors are not measured but a 
variable C influenced by U1 and U2, is measured. Adjusting Y for C reduces the residual 
variance of Y, but also introduces a component of the variance specific to C. In (c) the 
covariate shares factors with Y, but is also influenced by X. When the effect of X on C is 
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concordant with the effect of X on Y, this can induce a power loss. In (d) Y is not associated 
with the predictor and adjusting for C can induce false association signal by introducing the 
effect of X into the residual of Y.
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Figure 2. Examples of shared variance in real data and equivalent increases in sample size
Panel (a) shows the equivalent increase in sample size as a function of the variance of the 
outcome explained by covariates assuming initial sample sizes ranging from 100 to 10,000. 
Panels (b) and (c) show the distribution of variance explained by other variables for 79 
metabolites from the PANSCAN study, and a random sub-sample of expression abundance 
estimates from 79 genes in the gEUVADIS study. The size of the bar corresponds to the total 
variance explained of each outcome by other available covariates, while the relative 
contribution of these covariates to each outcome is illustrated with different sets of random 
colors for each bar.
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Figure 3. Conditional and unconditional distribution
Example of inclusion area based on the distribution of , the estimated effect between the 
predictor X and the covariate C under the null hypothesis of no association between X and C 
( ) and no association between X and the outcome Y ( ). (a) presents the standard 
95% confidence interval (green area) corresponding to p-value <0.05 unconditional on . (b) 
and (c) show both the unconditional (blue curve) and conditional (pink curve) distribution of 
. CMS combines the two, setting an inclusion area (blue+pink shaded), while weighting 
both interval by a factor depending on the correlation between Y and C, which equals 0.5 in 
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(b) and 0.8 in (c). Plots were drawn assuming all variables are standardized, using a sample 
size of 10,000, an overall variance of Y explained of 0.7,  and a multivariate test of 
association between all covariates and Y with a p-value ( ) of 0.3.
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Figure 4. Power and robustness
QQ plots under the null and alternate distributions of p-values from a series of simulations. 
We compare four statistical tests: a standard marginal univariate test (LR); the optimally 
adjusted test (OPT) that includes as covariates only the outcomes not associated with the 
predictor; CMS; and a univariate test that include as covariate all outcomes with a p-value 
for association with the predictor above 0.1 (FT). Grey boxes show the genomic inflation 
factor  for the null models (upper panels), and estimated power at an α threshold of 
5×10−7 (to correct for 100,000 tests) for the alternative model (lower panels). Null models 
also include the 95% confidence interval of the −log10(p-values), displayed as a grey cone 
around the diagonal. Simulations were taken from 100,000 datasets including 10 (a), 40 (b) 
and 80 (c) outcomes under a null model (upper panels), where a predictor of interest is not 
associated with a primary outcome but is associated with either 0%, 15% or 35% of the 
other outcomes with probability 0.75, 0.2 and 0.05 respectively, and under the alternative 
(lower panels), where the predictor is associated with the primary outcome only. The 
variance of the primary outcome that can be explained by the other outcomes was randomly 
chosen from [25%, 50%, 75%] with equal probability.
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Figure 5. Analysis of the gEUVADIS data
−log10(p-values) of the most significant SNP per gene obtained by CMS (y-axis) and linear 
regression (LR, x-axis) from a genome-wide cis-eQTL mapping of 11,675 genes in 375 
individuals from the gEUVADIS study. For illustration purposes we truncated the plots at 
−log10(p-value)=30. Both CMS and LR adjusted for 10 PEER factors, while the CMS 
analysis also included 0 to 50 additional covariates per SNP/gene pair tested. We considered 
a stringent significance threshold of 1.4×10−8 to account for the approximately 3.5 million 
tests and derived the number of gene showing at least one cis-eQTL with LR only (blue), 
CMS only (red), both approaches (turquoise), or neither (grey).
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